Natalie Brown
Nurse Practitioner · Hot Springs, ARNPI 1831662246
Payments from drug & device makers
Across 296 payments — averaging $13.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$1K
- Amgen$332
- AbbVie$281
- Novo Nordisk$259
- Sanofi-aventis U.S. LLC$231
- Bayer$222
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,925100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 123 | $1,129 |
| Amgen | 26 | $332 |
| AbbVie | 17 | $281 |
| Novo Nordisk | 26 | $259 |
| Sanofi-aventis U.S. LLC | 15 | $231 |
| Bayer | 14 | $222 |
| Novartis | 12 | $212 |
| Radius Health, Inc. | 6 | $172 |
| Tandem Diabetes Care, Inc. | 7 | $155 |
| Lilly USA, LLC | 8 | $152 |
| Boehringer Ingelheim | 7 | $140 |
| AstraZeneca(2 entities) | 8 | $137 |
| Medtronic | 6 | $96 |
| Insulet Corporation | 4 | $93 |
| Antares Pharma, Inc. | 3 | $53 |
| BETA Bionics, Inc. | 2 | $53 |
| Corcept Therapeutics | 3 | $46 |
| Boston Scientific | 2 | $31 |
| Abbott | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$3,925 in reported general payments places this provider in the 90th percentile of 697 nurse practitioner providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 598 | $685,355 |
| ProliaDenosumab | 138 | $241,520 |
| FarxigaDapagliflozin Propanediol | 225 | $194,801 |
| JardianceEmpagliflozin | 119 | $147,094 |
| Tresiba Flextouch U-100Insulin Degludec | 178 | $136,931 |
| MounjaroTirzepatide | 107 | $120,956 |
| TrulicityDulaglutide | 75 | $94,657 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 37 | $91,066 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 87 | $85,158 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 157 | $80,507 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 481 | $72,858 |
| JanuviaSitagliptin Phosphate | 74 | $65,150 |
| RybelsusSemaglutide | 43 | $63,945 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 138 | $41,852 |
| Humalog Kwikpen U-100Insulin Lispro | 98 | $36,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog, Levemir | $259 | $775,585689 claims |
| AmgenProlia, Evenity (2 Syringes) | $332 | $332,586175 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $152 | $220,543224 claims |
| AstraZenecaFarxiga | $137 | $194,801225 claims |
| Boehringer IngelheimJardiance | $140 | $147,094119 claims |
| AbbVieSynthroid | $281 | $5,01174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 697 nurse practitioner providers in Arkansas.
Other nurse practitioner in Hot Springs
- Tiffany McConathyHot Springs$54K
- Virginia LaliberteHot Springs$21K
- Samantha WidemanHot Springs$14K
- Cody WilliamsHot Springs$12K
- Nan MeansHot Springs$7K
- Ragan ArrisonHot Springs$7K
- Laci PattonHot Springs$7K
- Samantha BollanHot Springs$7K
- Kayla HarringtonHot Springs$6K
- Mindy FarmerHot Springs$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.